Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. director David Charles Lubner reported a bona fide gift of 53,625 shares of Common Stock on April 24, 2026. The transfer was recorded at $0.00 per share, and his directly owned holdings of this stock are now reported as 0 shares following the gift.

Insider Trade Summary

53,625 shares gifted

Mixed 1 txn

Insider Lubner David Charles

Role null

Type	Security	Shares	Price	Value
Gift	Common Stock	53,625	$0.00	--

Holdings After Transaction: Common Stock — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Shares gifted: 53,625 shares Reported gift price: $0.00 per share Shares held after transaction: 0 shares +1 more

4 metrics

Shares gifted 53,625 shares Bona fide gift of Common Stock on April 24, 2026

Reported gift price $0.00 per share Price per share for the bona fide gift transaction

Shares held after transaction 0 shares Director’s directly owned Common Stock following the gift

Gift transactions count 1 transaction Single bona fide gift reported in this Form 4

Key Terms

Common Stock, bona fide gift

2 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

bona fide gift financial

"transaction_code_description: "Bona fide gift""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lubner David Charles

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/24/2026		G		53,625	D	$0.00	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ron Caponigro, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dyne Therapeutics (DYN) report in this Form 4?

Dyne Therapeutics reported that director David Charles Lubner made a bona fide gift of 53,625 shares of Common Stock. The transaction was recorded at $0.00 per share, reflecting a non-cash transfer rather than a market sale or purchase.

How many Dyne Therapeutics (DYN) shares did David Charles Lubner transfer?

David Charles Lubner transferred 53,625 shares of Dyne Therapeutics Common Stock as a bona fide gift. This non-cash disposition reduced his directly owned holdings in the company to 0 shares as reported following the transaction on April 24, 2026.

Was the Dyne Therapeutics (DYN) insider transaction a sale or a gift?

The transaction was a bona fide gift, not an open-market sale. Director David Charles Lubner disposed of 53,625 shares of Common Stock at a reported price of $0.00 per share, indicating no monetary consideration was received for the transfer.

What is David Charles Lubner’s Dyne Therapeutics (DYN) shareholding after the gift?

After the reported bona fide gift of 53,625 Common Stock shares, David Charles Lubner’s directly owned holdings are shown as 0 shares. The Form 4 does not list any remaining derivative positions for him in Dyne Therapeutics following this transaction.

Does the Dyne Therapeutics (DYN) Form 4 show any derivative securities for the director?

The Form 4 shows no derivative securities transactions and an empty derivative holdings summary for director David Charles Lubner. This indicates no options, warrants, or similar derivative positions are reported for him in connection with this filing.